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Introduction
Fatigue is a poorly understood symptom in multiple sclerosis 
(MS), despite its high frequency and influence on the qual-
ity of life [1]. Studies suggest a multifactorial model, sepa-
rating between primary MS-related and secondary factors 
[1, 2]. Primary factors entail disease activity and immune 
activation, in particular the influence of endocrines and 
proinflammatory cytokines [3–6], as well as alternations to 
brain areas suggestive to be involved in the perception of 
fatigue [7, 8]. Secondary mechanisms involve comorbidi-
ties such as additional autoimmune disease and psychiatric 
disorders [3, 4]. Multiple studies found poor sleep quality to 
be linked with higher fatigue levels and additionally associ-
ated with increased depression scores [9, 10]. Indeed, major 
depressive disorder (MDD) is one of the most common 
fatigue-influencing comorbidities in patients with MS [11, 
12]. MDD is not only highly prevalent in MS patients but is 
also associated with immune system alterations and hyper-
activity of the hypothalamic–pituitary–adrenal axis with 
subsequently altered inflammatory neuroendocrine factors 
and is thus directly linked to primary diseases mechanisms 
in MS [11, 13–16].
Our goal was to describe the evolution of fatigue in MS 
compared with a healthy population, especially in regard to 
primary and secondary factors associated with fatigue.
Patients and methods
For this retrospective analysis, we selected patients and con-
trols from ongoing observational cohort studies (Berlin-CIS-
COHORT, NCT01371071, and VIMS, EA1/182/10). Inclu-
sion criteria were a diagnosis of CIS or RRMS according 
to the 2010 McDonald criteria. Of 170 screened patients, 
133 patients were included (CIS N = 100, RRMS N = 33, 
median follow-up time (time between first and last visit, 
inter-quartile range (IQR)): 2.40 years (1.45, 3.81)) and 
30 healthy controls (HCs) matched for age (p = 0.784) and 
sex (p = 0.072). 16 HCs had no relevant comorbidities. 
Inclusion criteria were a baseline diagnosis of CIS or early 
RRMS according to the McDonald criteria (revised version 
2010) [17] with less than 3 years since disease onset, and 
a minimum age of 18. Exclusion criterium was a missing 
FSS questionnaire. The cohort studies were approved by the 
local ethics committee and conducted in accordance with 
the Declaration of Helsinki. All participants gave written 
informed consent.
Disability was assessed using the expanded disability 
status scale (EDSS). Fatigue was assessed using the fatigue 
severity scale (FSS) and categorized into non-fatigued 
(FSS ≤ 4.0), borderline fatigued (4.0 < FSS < 5.0), or 
fatigued (FSS ≥ 5.0). Depressive symptoms and sleep quality 
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were measured with Beck’s depression inventory (BDI-II, 
cut-off: 13) and the Pittsburgh Sleep Quality Index (PSQI, 
cut-off: 6), respectively.
Whole-brain lesion volume was obtained using the lesion 
segmentation toolbox with manual correction in ITK-SNAP 
using MPRAGE and FLAIR images of a 3 T MRI scanner 
(MAGNETOM Trio Tim Siemens, Erlangen, Germany).
Group comparisons were performed with χ2 (test statistic: 
χ2) or Wilcoxon test (test statistic: W). Correlations were 
analyzed using parametric or Spearman’s correlation. All 
tests were performed using R 3.6.0. P values < 0.05 were 
considered significant.
Results
We found no differences in fatigue distribution between 
patients and HCs at baseline (HC vs. patients: χ2 = 3.135, 
p = 0.209) (Table 1).
During follow-up, 88 patients had a consistent fatigue sta-
tus (fatigued = 10 [8%], non-fatigued = 78 [59%]). 45 (34%) 
patients changed fatigue status (inconsistent fatigue (IF)): 
Twelve patients lost their fatigue status at follow-up (9%), 
whereas 8 patients developed fatigue at follow-up (6%). The 
remaining patients showed only a minor change of scores 
and switched from or to borderline fatigued (Fig. 1, black 
arrows). The majority (13 [81.25%]) of HCs had a consist-
ent fatigue status, with only one (6.25%) HC categorization 
changing from borderline to non-fatigued at follow-up. 
Fewer patients (N = 78; 59%) were consistently catego-
rized as not fatigued than HCs (N = 13; 81%). More patients 
(N = 45; 34%) than HCs (N = 1; 6.25%) had an unstable 
fatigue status over time (p = 0.012, χ2 = 6.309).
We then analyzed primary and secondary factors in 
patients (n = 30) categorized as consistently high fatigued 
(CF, n = 10, Fig. 1, yellow arrow) or IF (n = 20, Fig. 1, green 
and red arrows). Regarding primary factors, 7 (23%) patients 
had an EDSS increase (≥ 1) at follow-up (4 CF, 3 IF). At 
baseline, EDSS was higher in fatigued than non-fatigued 
patients (p = 0.021). Changes in EDSS and in the fatigue 
group were associated (p = 0.042). In contrast, lesion vol-
ume did not correlate with fatigue at baseline (R = 0.680, 
p = 0.502) or follow-up (R = 0.847, p = 0.406) and was not 
associated with consistency of fatigue status ([W] 699.0, 
p = 0.774).
Investigating secondary mechanisms, the majority of IF 
(18 [90%]) and CF (9 [90%]) patients showed comorbidi-
ties. 8 IF (40%) and 6 CF (60%) had comorbid autoimmune 
disorders. Thyroid disorders were observed in 1 CF (10%) 
with Hashimoto-thyroiditis, 4 IF (20%) with hypothyroid-
ism (2 IF (10%) with Hashimoto-thyroiditis, 1 IF (5%) after 
thyroidectomy due to focal thyroid autonomy, 1 IF (5%) 
not further classified) and 1 IF (5%) with an elevated Thy-
roid-Stimulating-Hormone level (not further classified). 9 
IF (45%) and 8 CF (80%) showed psychiatric comorbidi-
ties: Depressive symptoms were present in 8 IF (40%) and 
Table 1  Cohort description
BDI Beck’s Depression Inventory, EDSS expanded disability status scale, FSS Fatigue Severity Scale, IQR 
inter-quartile range, m male, N number, SD standard deviation
HC Patients
Subjects [N] 30 133
Subjects with longitudinal data [N] 16 133
Sex [m (%)] 15 (50.0) 44 (33.1)
Age at baseline [mean (SD)] 33.6 (12.0) 32.8 (9.1)
Follow-up time in years [median (IQR)] 2.0 [1.1, 2.7] 2.4 [1.5, 3.8]
Time since onset at baseline [months; median (IQR)] 4.0 [3.0, 5.0]
EDSS at baseline [median (IQR)] 1.5 [1.0, 2.0]
BDI Score at baseline [median (IQR) N = 80]
(available for 30 HC and 50 patients)
0.50 [0.00, 6.75] 6.00 [2.00, 11.00]
Subjects without depressive symptoms at baseline [N (%)] 30 (100.0%) 46 (34.6%)
Subjects with depressive symptoms at baseline [N (%)] 0 (0.0%) 4 (3.0%)
FSS Score at baseline [median (IQR)] 2.34 [1.67, 2.92] 2.50 [1.53, 4.11]
Not fatigued subjects at baseline according to FSS [N (%)] 26 (86.7%) 99 (74.4%)
Borderline fatigued subjects at baseline according to FSS [N (%)] 3 (10.0%) 14 (10.5%)
Fatigued subjects at baseline according to FSS [N (%)] 1 (3.3%) 20 (15.0%)
FSS score at last visit [median (IQR)] 2.45 [1.67, 3.45] 2.28 [1.78, 3.81]
Not fatigued subjects at last visit [N (%)] 14 (87.5%) 99 (74.4%)
Borderline fatigued subjects at last visit [N (%)] 1 (6.3%) 12 (9.0%)
Fatigued subjects at last visit [N (%)] 1 (6.3%) 22 (16.6%)
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8 CF (80%). In patients, FSS and BDI-II were associated 
(χ2 = 27.6, p < 0.0001). Of the 22 patients (15 IF, 7 CF) with 
sleep quality data, 4 IF (27%) and 6 CF (86%) reported con-
sistently poor sleep.
Discussion
We observed a high prevalence and persistence of fatigue 
without a general alteration pattern in early MS compared 
with HCs. In our study at disease onset, only 15% of MS/CIS 
patients reported fatigue. This is in contrast to two previous 
studies from one center, which reported frequencies of up 
to 45% [18, 19]. Concerning primary fatigue, disability and 
disability worsening were associated with fatigue at onset 
and development of fatigue, whereas MRI T2-weighted 
lesion load did not contribute. Most relevant in our study 
were secondary factors of fatigue, namely concomitant auto-
immune and mood disorders as well as poor sleep.
In contrast, primary mechanisms hardly are associ-
ated with a higher prevalence of fatigue [3, 14]. Thus, MS 
patients appear to be either prone to fatigue or stay stable 
not fatigued after their first event. Disease progression as the 
most important primary mechanism appears to play only a 
minor role since fatigue did not increase over time and was 
not associated with disease activity. However, increasing dis-
ability (e.g. newly developed sensory disorder or spasticity) 
might lead to perceived mobility difficulties, which could 
be felt as weakness or be interpreted as fatigue. As many 
patients are stable, not fatigued even though EDSS increases, 
a direct link between disability and fatigue is unlikely. Stud-
ies supporting this multifactorial highly interactive disease 
model have further found psychiatric comorbidities, such 
as mood and anxiety disorders, to be associated with higher 
EDSS scores leading to the assumption that also these 
comorbidities confound the correlation of EDSS and fatigue 
[12, 20–22].
Limitations of this study include the lack of data prior 
to the MS diagnosis and the shorter follow-up in HC. 
The low prevalence of fatigue may limit our sample’s 
representativeness.
To conclude, secondary factors have to be taken into 
account when assessing and managing fatigue in MS. These 
comorbidities may open an important avenue of interven-
tions in patients suffering from fatigue and should thus be 
evaluated before considering treatment options for primary 
fatigue. In contrast, primary factors of fatigue were less 
important in our sample of patients at disease onset.
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Fig. 1  Tracking changes in individual patient fatigue status (N = 133) 
from baseline to follow up. Patients with a consistent fatigue catego-
rization (CF) are highlighted in orange and patients changing from 
fatigued to non-fatigued or from non-fatigued to fatigued (IF) are 
highlighted in green and red, respectively. CF Patients with a consist-
ent fatigue categorization, IF patients changing from fatigued to non-
fatigued or from non-fatigued to fatigued, N number
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